Tokyo city, Japan
Market Herald logo


Be the first with the news that moves the market
  • Regenerative medicine company, Regeneus, now has enough funds to go ahead with commercialisation in Japan
  • The company has made a share shortfall placement of almost 9.5 million shares, to a Japanese life-science investor
  • Combined with a Non-Renounceable Rights Issue and a private placement, this $750,000 placement brings the total raised to $5.5 million
  • Regeneus plans to commercialise Progenza, a cell therapy technology that treats osteoarthritis, by 2023
  • Shares are up 43.9 per cent after the news, trading for 9.5 cents each

Regeneus (RGS), today announced a $755,029 share placement with a Japanese institutional investor as part of its funding to commercialise in Japan.

A share shortfall of 9,437,872 shares was placed with the investor, who has experience with regenerative medicine in Japan, at a price of $0.08 per share.

The shortfall shares were part of a Rights Issue and, in addition to $2.34 million from a private placement, brings the total capital raised to $5.5 million. Regeneus CEO, Leo Lee said the placement is key to the company’s next step in Japan.

“The completion of the non-renounceable rights issue, together with our streamlined internal operations and pending Progenza licensing deal in Japan, Regeneus will be sufficiently funded to commercialisation in Japan,” he said.

Progenza is a cell therapy technology being developed to treat osteoarthritis and other musculoskeletal disorders. According to the company it also has the potential to treat other inflammatory disorders.

The Australian-based company is planning to continue clinical development, manufacturing and commercialisation of the product in Japan.

Regeneus has already reached a strategic collaboration and licensing agreement with AGC, a biopharmaceutical contract manufacturer in Japan. They will work together on the manufacture, clinical development and commercialisation of Progenza, specifically for the Japanese market.

Regeneus identified Japan as a key target market, in partly due to an existing accelerated approval process for regenerative medicine.

A Phase 1 trials of Progenza for osteoarthritis was completed successfully and preparations are underway for a Phase 2 clinical trial in Japan.

The market responded positively to the news, with shares up 43.9 per cent. They were trading for 9.5 cents each at 15:58 on November 19, 2029.

RGS by the numbers
More From The Market Herald
Race Oncology (ASX:RAC) - CEO, Phillip Lynch

" Race Oncology (ASX:RAC) posts nominal decline in cash

Race Oncology (RAC) has posted a nominal decline in cash and equivalents as of 30 September 2021 to $8.94 million, down from $9.32...
Prescient Therapeutics (ASX:PTX) - Managing Director and CEO, Steven Yatomi Clarke

" Prescient Therapeutics (ASX:PTX) logs timely progress across anti-cancer programs in Q3

Prescient Therapeutics (PTX) says it is poised to reach value-adding milestones across its anti-cancer programs after wrapping up the September quarter with $14.8...
Neuren Pharmaceuticals (ASX:NEU) - CEO, Jon Pilcher

" Neuren Pharmaceuticals (ASX:NEU) highlights trial progress in September quarterly

Neuren Pharmaceuticals (NEU) has released its September quarterly report, highlighting the progress with its upcoming clinical trials.

" Invion (ASX:IVX) sees complete regression of tumours in breast cancer trial

Invion (IVX) shares have soared following its latest trial results, demonstrating a complete regression in tumours following in vivo treatment.